Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

CONCLUSION: CS in patients undergoing NAC for BR/LA pancreatic cancer does not incur oncologic detriment. The incorporation of CS into NAC treatment sequencing may allow a greater proportion of patients to proceed to curative-intent surgery.PMID:34724125 | DOI:10.1245/s10434-021-10991-2

Source: Ann Oncol - November 1, 2021 Category: Cancer & Oncology Authors: Roberto Alva-Ruiz Lavanya Yohanathan Jennifer A Yonkus Amro M Abdelrahman Lindsey A Gregory Thorvadur R Halfdanarson Amit Mahipal Robert R McWilliams Wen Wee Ma Christopher L Hallemeier Rondell P Graham Travis E Grotz Rory L Smoot Sean P Cleary David M Na Source Type: research